- Home
- PANL vs DMAC Comparison
PANL vs DMAC Comparison
Compare PANL & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PANL
- DMAC
- Stock Information
- Founded
- PANL 1996
- DMAC 2000
- Country
- PANL United States
- DMAC United States
- Employees
- PANL N/A
- DMAC N/A
- Industry
- PANL Marine Transportation
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- PANL Consumer Discretionary
- DMAC Health Care
- Exchange
- PANL Nasdaq
- DMAC Nasdaq
- Market Cap
- PANL 328.2M
- DMAC 310.1M
- IPO Year
- PANL N/A
- DMAC N/A
- Fundamental
- Price
- PANL $5.33
- DMAC $5.71
- Analyst Decision
- PANL Strong Buy
- DMAC Strong Buy
- Analyst Count
- PANL 1
- DMAC 3
- Target Price
- PANL $9.00
- DMAC $12.33
- AVG Volume (30 Days)
- PANL 218.4K
- DMAC 310.7K
- Earning Date
- PANL 08-07-2025
- DMAC 08-12-2025
- Dividend Yield
- PANL 3.78%
- DMAC N/A
- EPS Growth
- PANL N/A
- DMAC N/A
- EPS
- PANL 0.16
- DMAC N/A
- Revenue
- PANL $579,781,169.00
- DMAC N/A
- Revenue This Year
- PANL $13.00
- DMAC N/A
- Revenue Next Year
- PANL N/A
- DMAC N/A
- P/E Ratio
- PANL $32.83
- DMAC N/A
- Revenue Growth
- PANL 15.10
- DMAC N/A
- 52 Week Low
- PANL $3.93
- DMAC $3.19
- 52 Week High
- PANL $7.50
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- PANL 59.78
- DMAC 57.83
- Support Level
- PANL $5.21
- DMAC $5.90
- Resistance Level
- PANL $5.48
- DMAC $6.16
- Average True Range (ATR)
- PANL 0.16
- DMAC 0.38
- MACD
- PANL 0.03
- DMAC -0.03
- Stochastic Oscillator
- PANL 75.81
- DMAC 61.02
About PANL Pangaea Logistics Solutions Ltd.
Pangaea Logistics Solutions Ltd and its subsidiaries provide seaborne drybulk logistics and transportation services. It transports various drybulk cargoes including grains, coal, iron, ore, pig, iron, hot briquetted iron, bauxite, alumina, cement clinker, dolomite, and limestone. The company provides ocean transportation services to clients utilizing an ocean-going fleet of motor vessels in the Handymax, Supramax, Ultramax, Panamax, and Post-Panamax segments. Its services include cargo loading, cargo discharge, vessel chartering, voyage planning, and technical vessel management. The company derives all of its revenues from contracts of affreightment, voyage charters and time charters. Geographically, it derives key revenue from the United States, followed by Canada, Germany, and others.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.